Sana Biotechnology (NASDAQ:SANA) Rating Lowered to “Hold” at Zacks Research

Sana Biotechnology (NASDAQ:SANA) was downgraded by investment analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report released on Tuesday,Zacks.com reports.

Several other analysts have also recently weighed in on the company. Bank of America raised their price target on Sana Biotechnology from $6.00 to $7.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. Wall Street Zen lowered Sana Biotechnology from a “hold” rating to a “sell” rating in a research note on Saturday, February 7th. Wedbush increased their target price on shares of Sana Biotechnology from $5.00 to $6.00 and gave the company an “outperform” rating in a report on Friday, November 7th. HC Wainwright dropped their target price on Sana Biotechnology from $9.00 to $7.00 and set a “buy” rating for the company in a report on Wednesday. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sana Biotechnology in a research note on Monday, December 29th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Sana Biotechnology presently has an average rating of “Moderate Buy” and an average price target of $7.83.

Sana Biotechnology Trading Down 9.4%

Shares of SANA stock traded down $0.36 during trading hours on Tuesday, reaching $3.46. The stock had a trading volume of 2,708,451 shares, compared to its average volume of 2,265,759. The stock’s fifty day simple moving average is $4.30 and its 200 day simple moving average is $4.14. The firm has a market capitalization of $921.64 million, a PE ratio of -3.57 and a beta of 1.96. Sana Biotechnology has a 12 month low of $1.26 and a 12 month high of $6.55.

Sana Biotechnology (NASDAQ:SANA) last posted its earnings results on Tuesday, March 3rd. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.03). As a group, equities research analysts anticipate that Sana Biotechnology will post -1.16 EPS for the current fiscal year.

Hedge Funds Weigh In On Sana Biotechnology

Several hedge funds and other institutional investors have recently modified their holdings of the company. Baillie Gifford & Co. lifted its holdings in Sana Biotechnology by 13.6% in the third quarter. Baillie Gifford & Co. now owns 11,436,503 shares of the company’s stock valued at $40,600,000 after acquiring an additional 1,371,775 shares during the period. Vanguard Group Inc. raised its position in Sana Biotechnology by 19.9% in the third quarter. Vanguard Group Inc. now owns 9,128,973 shares of the company’s stock worth $32,408,000 after acquiring an additional 1,517,474 shares during the period. State Street Corp boosted its stake in shares of Sana Biotechnology by 20.6% during the 4th quarter. State Street Corp now owns 8,054,841 shares of the company’s stock worth $32,783,000 after acquiring an additional 1,374,300 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Sana Biotechnology by 20.3% during the 4th quarter. Geode Capital Management LLC now owns 4,118,138 shares of the company’s stock valued at $16,763,000 after acquiring an additional 694,606 shares during the period. Finally, Marex Group plc bought a new stake in shares of Sana Biotechnology during the 2nd quarter valued at $10,423,000. 88.23% of the stock is owned by institutional investors.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.